Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Lobat Hashemi"'
Autor:
Tamela Stuchiner, Lindsay Lucas, Elizabeth Baraban, Kateri J. Spinelli, Chiayi Chen, Alden Smith, Lobat Hashemi, Stanley Cohan
Publikováno v:
BMC Neurology, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Nine oral disease-modifying therapies (DMTs) have been approved for the treatment of multiple sclerosis (MS) in the United States. Few studies have examined self-reported quality of life (QoL) and functional status outcomes among
Externí odkaz:
https://doaj.org/article/577d2d8af10a4fa78215a4ec0752500e
Autor:
Antonio Bertolotto, Rafael Arroyo, Elisabeth G. Celius, Giancarlo Comi, Eva Kubala Havrdova, William David Honeycutt, Samuel F. Hunter, Guillermo Izquierdo, Barbara Kornek, Tamara Miller, Dimos D. Mitsikostas, Barry A. Singer, Tjalf Ziemssen, Luke Chung, Nadia Daizadeh, Salman Afsar, Lobat Hashemi, Peter Senior
Publikováno v:
Neurology and Therapy, Vol 9, Iss 2, Pp 443-457 (2020)
Plain Language Summary This study looked at alemtuzumab, an approved treatment for multiple sclerosis (MS). People who receive alemtuzumab may develop thyroid problems. The researchers wanted to know whether people who developed thyroid problems with
Externí odkaz:
https://doaj.org/article/3bcc37fc46e84de69be4eb2c49df7148
Publikováno v:
BMC Neurology, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Research is needed to examine differences in multiple sclerosis (MS) prevalence by race-ethnicity. The goal of this study was to quantify MS prevalence in a health care system in Northern California and examine differences in prev
Externí odkaz:
https://doaj.org/article/a02053394c0f429db2338aa82576f2f6
Publikováno v:
Neurology and Therapy, Vol 8, Iss 1, Pp 121-133 (2018)
Abstract Introduction Despite the increasing age of the multiple sclerosis (MS) patient population, data are lacking on MS patients in later life. This retrospective study investigated treatment patterns, healthcare resource utilization (HCRU), and h
Externí odkaz:
https://doaj.org/article/972fc8b5638844fd9525fc2f5337ff05
Publikováno v:
Inquiry: The Journal of Health Care Organization, Provision, and Financing, Vol 44 (2007)
In March 2003, Massachusetts increased the premiums it charges to most enrollees in its CommonHealth-Working (CH-W) program. This study evaluates the impact of the premium change on disenrollment using a comparison group methodology. The findings ind
Externí odkaz:
https://doaj.org/article/eeea8c88871f4a849956450eafe132e7
Autor:
Kevin Duhrkopf, Nupur Greene, Sandipan Bhattacharjee, Kristin Kollecas, Lobat Hashemi, Zufan Yegezu
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Sandipan Bhattacharjee,1 Zufan Yegezu,2 Kristin Kollecas,3 Kevin Duhrkopf,3 Lobat Hashemi,3 Nupur Greene3 1Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA; 2Department of Pharmacy Practice and Science
Autor:
Kateri J. Spinelli, Elizabeth Baraban, Lobat Hashemi, Stanley Cohan, Lindsay Lucas, Chiayi Chen, Tamela Stuchiner, Alden Smith
Publikováno v:
BMC Neurology, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Neurology
BMC Neurology
Background Nine oral disease-modifying therapies (DMTs) have been approved for the treatment of multiple sclerosis (MS) in the United States. Few studies have examined self-reported quality of life (QoL) and functional status outcomes among patients
Autor:
Luke Chung, Samuel F. Hunter, Barry A Singer, Antonio Bertolotto, Guillermo Izquierdo, Lobat Hashemi, Tjalf Ziemssen, Nadia Daizadeh, William David Honeycutt, Elisabeth Gulowsen Celius, Dimos-Dimitrios Mitsikostas, Salman Afsar, Barbara Kornek, Tamara Miller, Peter A. Senior, Rafael Arroyo, Giancarlo Comi, Eva Havrdova
Publikováno v:
Neurology and Therapy, Vol 9, Iss 2, Pp 443-457 (2020)
Neurology and Therapy
Neurology and Therapy
Introduction In clinical trials of alemtuzumab, autoimmune thyroid adverse events (AEs) were frequent. Here, we assess the impact of thyroid AEs on health-related quality of life (HRQL) in alemtuzumab-treated patients with relapsing-remitting multipl
Publikováno v:
Neurology and Therapy, Vol 8, Iss 1, Pp 121-133 (2018)
Neurology and Therapy
Neurology and Therapy
Introduction Despite the increasing age of the multiple sclerosis (MS) patient population, data are lacking on MS patients in later life. This retrospective study investigated treatment patterns, healthcare resource utilization (HCRU), and healthcare
Autor:
Sandipan Bhattacharjee, Zufan Yegezu, Kristin Kollecas, Kevin Duhrkopf, Nupur Greene, Lobat Hashemi
Publikováno v:
Research in socialadministrative pharmacy : RSAP. 18(11)
Scarce data exists regarding United States (US) national-level work productivity loss among adults with Multiple Sclerosis (MS).To address this significant knowledge gap, we examined the national-level productivity loss among adults (18≤ age ≤64